Aier(SZ:300015)2022-04-25 16:00Financial Performance - The company's revenue for Q1 2022 was ¥4,168,634,167.01, representing an increase of 18.72% compared to ¥3,511,190,964.34 in the same period last year[4] - Net profit attributable to shareholders was ¥610,600,966.52, up 26.15% from ¥484,020,052.47 year-on-year[4] - Basic earnings per share rose to ¥0.1143, reflecting a growth of 26.58% from ¥0.0903 in the same quarter last year[4] - Operating profit for the current period was ¥908,090,797.25, representing a growth of 15.3% from ¥787,868,891.91 in the previous period[26] - The company reported a total profit of ¥889,621,495.47, which is a 23.3% increase from ¥721,492,676.00 in the previous period[26] Cash Flow - The net cash flow from operating activities increased by 39.36% to ¥1,033,576,295.45, compared to ¥741,642,735.42 in the previous year[4] - Cash generated from operating activities was ¥4,088,028,238.62, compared to ¥3,413,792,000.19 in the previous period, indicating a rise of 19.7%[28] - Cash inflow from operating activities increased by 19.40% to ¥4,114,993,219.20, compared to ¥3,446,371,122.15 in the previous year[11] - The company reported a total operating cash outflow of ¥3,081,416,923.75, an increase from ¥2,704,728,386.73 in the previous year[29] - The ending balance of cash and cash equivalents was ¥4,036,194,074.45, down from ¥3,465,903,057.71 in Q1 2021[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥22,327,827,649.72, a 2.19% increase from ¥21,849,010,103.36 at the end of the previous year[4] - Total liabilities decreased to CNY 9,477,885,614.17 from CNY 9,624,943,005.59, a reduction of about 1.5%[24] - The company's equity attributable to shareholders increased to CNY 11,861,714,880.07 from CNY 11,309,739,829.99, reflecting a growth of approximately 4.9%[24] - The company's cash and cash equivalents decreased to CNY 4,089,088,008.15 from CNY 4,402,316,633.69 at the beginning of the year, reflecting a decline of approximately 7.1%[21] Investment and R&D - The company reported a significant increase in investment income, which rose by 98.74% to ¥20,751,408.33 from ¥10,441,247.48 year-on-year[10] - Research and development expenses increased by 21.23% to ¥57,175,077.44, compared to ¥47,161,753.07 in the previous year, indicating a focus on innovation[10] - The company plans to raise up to CNY 353,555.37 million through a private placement to fund multiple expansion projects across various locations[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 323,039[13] - The largest shareholder, Aier Medical Investment Group Co., Ltd., holds 35.07% of shares, totaling 1,896,021,039 shares[13] - Chen Bang, a natural person, holds 15.81% of shares, totaling 854,835,474 shares, with 641,126,605 shares pledged[13] - The top ten shareholders collectively hold 79.99% of the shares, indicating a high concentration of ownership[14] - The company has no preferred shareholders as indicated in the report[14] Other Financial Activities - The company has engaged in financing and securities lending activities, but no specific details were provided[15] - The report indicates that there are no related party transactions among the remaining circulating shareholders[14] - The company is actively managing its shareholding structure, with significant portions of shares pledged by key shareholders[13] - The company granted 15,558,943 shares of restricted stock at a price of CNY 20.71 per share to 1,146 incentive objects as part of its equity incentive plan[20]